Lancet Oncol 2020 Mar 20
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Related Questions
New answer by Medical Oncologist at University of Arizona Cancer Center (September 14, 2020)
Honestly, the response to these inhibitors with FGFR alterations beyond FGFR2 fusions is quite low in the data known to date. The initial infigratinib study had responses prim...